Aliases & Classifications for Colitis

MalaCards integrated aliases for Colitis:

Name: Colitis 12 74 29 54 6 44 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060180
MeSH 44 D003092
NCIt 50 C26723
SNOMED-CT 67 64226004
ICD10 32 K52.9
UMLS 71 C0009319

Summaries for Colitis

Disease Ontology : 12 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary : Colitis is related to ulcerative colitis and microscopic colitis. An important gene associated with Colitis is SYK (Spleen Associated Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Iron and Linaclotide have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and liver, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1755)
# Related Disease Score Top Affiliating Genes
1 ulcerative colitis 33.8 TNF SMAD4 NOD2 MPO IRGM IL23R
2 microscopic colitis 33.4 TNF IL2 IFNG HLA-DRB1
3 crohn's disease 33.3 TNF NOD2 MPO IRGM IL23R IL2
4 chemical colitis 33.2 TNF NOD2 IL1B IL17A IL10
5 inflammatory bowel disease 33.0 TNF NOD2 MPO IRGM IL23R IL2
6 crohn's colitis 33.0 TNF NOD2 IL2 IL1B IFNG CXCL8
7 inflammatory bowel disease 1 32.9 TNF NOD2 IRGM IL23R ATG16L1
8 amebiasis 32.9 TNF IL1B IL17A IL10 CXCL8
9 cholangitis, primary sclerosing 32.8 TNF NOD2 MPO IL17A IL10
10 irritable bowel syndrome 32.7 TNF IL1B IL10 CXCL8
11 pouchitis 32.6 TNF NOD2
12 diarrhea 32.6 TNF NOD2 MPO IL2 IL1B IL10
13 enterocolitis 32.6 TNF NOD2 IL10 CXCL8
14 gastroenteritis 32.6 TNF IL1B IL10 IFNG CXCL8
15 pyoderma gangrenosum 32.5 TNF NOD2 CXCL8
16 inflammatory bowel disease 25, autosomal recessive 32.4 IL10RB IL10RA IL10
17 cholangitis 32.3 TNF NOD2 MPO IL2 IL10 HLA-DRB1
18 sclerosing cholangitis 32.3 TNF NOD2 MPO IL2 IL10 HLA-DRB1
19 ileitis 32.1 TNF NOD2 MPO IL17A ATG16L1
20 pyoderma 32.0 TNF NOD2 IL1B CXCL8
21 proteasome-associated autoinflammatory syndrome 1 31.9 TNF MPO IL1B IL17A IL10 IFNG
22 peritonitis 31.8 TNF MPO IL1B IL10 CXCL8
23 dysentery 31.8 TNF MPO IL1B IL10 CXCL8
24 hypereosinophilic syndrome 31.8 MPO IL2 IL10 IFNG CXCL8
25 celiac disease 1 31.8 TNF NOD2 IL23R IL2 IL1B IL17A
26 gastritis 31.8 TNF IL1B IL17A IL10 CXCL8
27 ileocolitis 31.7 TNF NOD2 ATG16L1
28 appendicitis 31.7 TNF MPO IL2 IL1B IL17A IL10
29 allergic disease 31.7 TNF SYK MPO IL2 IL1B IFNG
30 autoimmune disease 31.7 TNF SYK MPO IL23R IL2 IL1B
31 ileus 31.6 TNF IL1B IL10
32 pancreatitis 31.6 TNF SMAD4 IL1B IL10
33 erythema nodosum 31.6 TNF NOD2 IL1B IL10 IFNG CXCL8
34 purpura 31.6 TNF IL1B IL10 IFNG
35 acute pancreatitis 31.6 TNF MPO IL1B IL10 CXCL8
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.6 IL17A IL10 IFNG
37 spondylitis 31.6 TNF NOD2 IL23R IL1B IL17A IL10
38 neutropenia 31.6 TNF MPO IL2 IL1B IL10 IFNG
39 acquired immunodeficiency syndrome 31.6 TNF IL2 IL1B IL10 IFNG
40 graft-versus-host disease 31.6 TNF IL2 IL1B IL10 IFNG HLA-DRB1
41 liver cirrhosis 31.6 TNF IL1B IL10 HLA-DRB1 CTNNB1
42 toxic shock syndrome 31.6 TNF IL2 IL1B IL10 IFNG CXCL8
43 severe combined immunodeficiency 31.5 IL2 IL17A IL10 IFNG
44 spondyloarthropathy 1 31.5 TNF NOD2 IL23R IL17A
45 pneumonia 31.4 TNF MPO IL1B IL17A IL10 IFNG
46 bacterial infectious disease 31.4 TNF NOD2 IL1B IL17A IL10 IFNG
47 chronic granulomatous disease 31.4 TNF MPO IL1B IL17A IFNG CXCL8
48 psoriasis 31.4 TNF NOD2 IL23R IL2 IL1B IL17A
49 uveitis 31.4 TNF NOD2 IL2 IL1B IL17A IL10
50 pericarditis 31.4 TNF IL1B IFNG CXCL8

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.65 CHEK2 IL2 NOD2
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.65 CHEK2 IL10 IL1B IL2 MPO NOD2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CXCL8 IL10 IL17A IL1B MPO TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CXCL8 IL10 IL17A IL1B IL2 MPO
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 CHEK2

MGI Mouse Phenotypes related to Colitis:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 ABCB1 ATG16L1 CHEK2 CTNNB1 IFNG IL10
2 homeostasis/metabolism MP:0005376 10.39 ABCB1 ATG16L1 CHEK2 CTNNB1 IFNG IL10
3 immune system MP:0005387 10.33 ABCB1 ATG16L1 CHEK2 CTNNB1 IFNG IL10
4 digestive/alimentary MP:0005381 10.32 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
5 growth/size/body region MP:0005378 10.32 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
6 cardiovascular system MP:0005385 10.31 ABCB1 ATG16L1 CHEK2 CTNNB1 IFNG IL10
7 endocrine/exocrine gland MP:0005379 10.31 ABCB1 ATG16L1 CHEK2 CTNNB1 IFNG IL10
8 cellular MP:0005384 10.3 ATG16L1 CHEK2 CTNNB1 IFNG IL10 IL10RA
9 mortality/aging MP:0010768 10.13 ABCB1 ATG16L1 CHEK2 CTNNB1 IFNG IL10
10 integument MP:0010771 10.02 ATG16L1 CTNNB1 IFNG IL10 IL17A IL1B
11 liver/biliary system MP:0005370 9.97 ABCB1 CTNNB1 IFNG IL10 IL10RB IL2
12 neoplasm MP:0002006 9.81 CHEK2 CTNNB1 IFNG IL10 IL1B IL2
13 no phenotypic analysis MP:0003012 9.61 ABCB1 CTNNB1 IFNG IL10 IL17A IL2
14 respiratory system MP:0005388 9.23 CTNNB1 IFNG IL10 IL10RB IL17A IL2

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 337)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925 29936
2
Linaclotide Approved Phase 4 851199-59-2 65351
3
Ustekinumab Approved, Investigational Phase 4 815610-63-0
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Magnesium citrate Approved Phase 4 3344-18-1
6
Teicoplanin Approved, Investigational Phase 4 61036-62-2
7
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
8
Tofacitinib Approved, Investigational Phase 4 477600-75-2
9
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
10
Infliximab Approved Phase 4 170277-31-3
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Azathioprine Approved Phase 4 446-86-6 2265
13
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
14
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
15 Polyethylene glycol 3350 Phase 4
16 Iron Supplement Phase 4
17 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
18 Protective Agents Phase 4
19 Neuroprotective Agents Phase 4
20 Antiemetics Phase 4
21 polysaccharide-K Phase 4
22 Vaccines Phase 4
23 Cathartics Phase 4
24 Laxatives Phase 4
25 Picosulfate sodium Phase 4
26 Protein Kinase Inhibitors Phase 4
27 Antimalarials Phase 4
28 Gentamicins Phase 4
29 Antibiotics, Antitubercular Phase 4
30 Mesalamine Phase 4 89-57-6
31 Analgesics Phase 4
32 Dermatologic Agents Phase 4
33 Immunologic Factors Phase 4
34 Immunoglobulins Phase 4
35 Antibodies Phase 4
36 Antimetabolites Phase 4
37 Immunosuppressive Agents Phase 4
38 Tin Fluorides Phase 4
39 Immunoglobulins, Intravenous Phase 4
40 Anticonvulsants Phase 4
41 Immunoglobulin G Phase 4
42 gamma-Globulins Phase 4
43 Rho(D) Immune Globulin Phase 4
44
Allopurinol Approved Phase 3 315-30-0 2094
45
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
46
Vancomycin Approved Phase 3 1404-90-6 441141 14969
47
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
48
Ferric maltol Approved Phase 3 33725-54-1
49
Abatacept Approved Phase 3 332348-12-6 10237
50
Olsalazine Approved Phase 3 15722-48-2

Interventional clinical trials:

(show top 50) (show all 1142)
# Name Status NCT ID Phase Drugs
1 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Unknown status NCT02687724 Phase 4 Golimumab (GLM)
2 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
3 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
4 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Unknown status NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
5 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
6 A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination With Methotrexate for the Treatment of Patients With Ulcerative Colitis Unknown status NCT01716039 Phase 4 MTX 12.5;MTX 25;Adalimumab
7 Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab Unknown status NCT03151525 Phase 4 Azathioprine;Infliximab
8 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
9 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
10 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
11 Optimization of Golimumab Treatment in Ulcerative Colitis Unknown status NCT03669029 Phase 4 Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg;Golimumab treatment optimization.
12 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
13 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
14 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
15 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
16 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
17 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
18 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
19 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
20 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
21 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab
22 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
23 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
24 Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. Completed NCT01201122 Phase 4 Mesalamine
25 A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
26 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
27 Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
28 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
29 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
30 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
31 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
32 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
33 An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study) Completed NCT02646657 Phase 4 Vedolizumab 300 mg
34 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
35 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
36 Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis. Completed NCT01536535 Phase 4 Mesalazine;IV Corticosteroid;Oral Corticosteroids
37 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
38 A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET) Completed NCT03029143 Phase 4 Vedolizumab IV
39 An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab. Completed NCT02318667 Phase 4
40 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
41 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
42 A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST) Completed NCT02790138 Phase 4 Vedolizumab;Ciprofloxacin;Vedolizumab Placebo
43 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Completed NCT03124121 Phase 4 Golimumab
44 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
45 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
46 The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Recruiting NCT03591770 Phase 4
47 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial Recruiting NCT02770040 Phase 4 Infliximab
48 Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled Trial Recruiting NCT03581149 Phase 4 Sodium Picosulfate/Magnesium Citrate Laxative;2L polyethylene glycol/ascorbic acid
49 De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring Recruiting NCT04646187 Phase 4
50 VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target Recruiting NCT04259138 Phase 4

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

# Genetic test Affiliating Genes
1 Colitis 29

Anatomical Context for Colitis

The Foundational Model of Anatomy Ontology organs/tissues related to Colitis:

19
Colon

MalaCards organs/tissues related to Colitis:

40
Colon, T Cells, Liver, Neutrophil, Bone, Myeloid, Bone Marrow

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 30220)
# Title Authors PMID Year
1
Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. 61 54
20440854 2010
2
Colitis as a manifestation of infliximab-associated disseminated cryptococcosis. 54 61
19660974 2010
3
On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. 54 61
20144954 2010
4
Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. 54 61
20004202 2010
5
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. 61 54
20181893 2010
6
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 54 61
20228197 2010
7
TLR5 is not required for flagellin-mediated exacerbation of DSS colitis. 61 54
19774646 2010
8
Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. 54 61
20008145 2010
9
A feed-forward loop involving hyaluronic acid and toll-like receptor-4 as a treatment for colitis? 54 61
19879211 2009
10
The gut feeling of Treg cells: IL-10 is the silver lining during colitis. 54 61
19841645 2009
11
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. 54 61
19104936 2009
12
Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. 61 54
19450685 2009
13
All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. 54 61
19477911 2009
14
An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation. 54 61
19616541 2009
15
Blockage of the neurokinin 1 receptor and capsaicin-induced ablation of the enteric afferent nerves protect SCID mice against T-cell-induced chronic colitis. 54 61
19326358 2009
16
Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats. 54 61
19535420 2009
17
Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. 61 54
19446544 2009
18
Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons. 61 54
19470777 2009
19
Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. 54 61
19525396 2009
20
Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. 61 54
19403332 2009
21
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. 54 61
19359427 2009
22
Mitogen-activated protein kinase pathways contribute to hypercontractility and increased Ca2+ sensitization in murine experimental colitis. 61 54
19190174 2009
23
Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. 61 54
19250273 2009
24
Genomic analysis of sulfasalazine effect in experimental colitis is consistent primarily with the modulation of NF-kappaB but not PPAR-gamma signaling. 54 61
19365232 2009
25
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. 54 61
19285099 2009
26
Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. 54 61
19342675 2009
27
Tumor necrosis factor-alpha impairs intestinal phosphate absorption in colitis. 61 54
19196948 2009
28
Nitric oxide increases Wnt-induced secreted protein-1 (WISP-1/CCN4) expression and function in colitis. 54 61
19238344 2009
29
Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. 61 54
19238529 2009
30
Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. 54 61
19126671 2009
31
The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. 61 54
18612822 2009
32
Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. 61 54
19101538 2009
33
Protection from DNBS-induced colitis by the tachykinin NK(1) receptor antagonist SR140333 in rats. 61 54
19103194 2009
34
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. 54 61
18815359 2009
35
Dietary taurine attenuates dextran sulfate sodium (DSS)-induced experimental colitis in mice. 54 61
19239157 2009
36
Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. 61 54
18818316 2008
37
The beneficial effect of Rheum tanguticum polysaccharide on protecting against diarrhea, colonic inflammation and ulceration in rats with TNBS-induced colitis: the role of macrophage mannose receptor in inflammation and immune response. 54 61
18790466 2008
38
[Free hemoglobin and tumor necrosis factor-alpha in the blood of horses with colic or acute colitis]. 61 54
19086694 2008
39
Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. 54 61
18618633 2008
40
Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. 54 61
18827968 2008
41
Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-alpha in an experimental murine model of colitis. 61 54
18667332 2008
42
Treatment of severe steroid refractory ulcerative colitis. 61 54
18810767 2008
43
Blockade of adenosine A2B receptors ameliorates murine colitis. 54 61
18536750 2008
44
Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. 54 61
18599605 2008
45
Tumour necrosis factor alpha in segmental colitis associated with diverticula. 61 54
18049899 2008
46
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. 61 54
18535667 2008
47
Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. 54 61
18381351 2008
48
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. 61 54
18473420 2008
49
Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. 54 61
18334870 2008
50
Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. 54 61
18400195 2008

Variations for Colitis

ClinVar genetic disease variations for Colitis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SYK NM_003177.7(SYK):c.1649C>T (p.Ser550Phe) SNV Pathogenic 989386 9:93650098-93650098 9:90887816-90887816
2 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs) Deletion Pathogenic 128042 rs555607708 22:29091857-29091857 22:28695869-28695869
3 SYK NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr) SNV Pathogenic 989389 9:93650098-93650098 9:90887816-90887816
4 SYK NM_003177.7(SYK):c.1350G>A (p.Met450Ile) SNV Likely pathogenic 989237 9:93640021-93640021 9:90877739-90877739
5 SYK NM_003177.7(SYK):c.1024C>A (p.Pro342Thr) SNV Likely pathogenic 989387 9:93636974-93636974 9:90874692-90874692
6 CIITA NM_000246.3(CIITA):c.3344G>A (p.Ser1115Asn) SNV Uncertain significance 598994 rs138790505 16:11017111-11017111 16:10923254-10923254
7 FLNA NM_001110556.2(FLNA):c.7463C>A (p.Thr2488Asn) SNV Uncertain significance 465020 rs909387820 X:153578106-153578106 X:154349738-154349738
8 SYK NM_003177.7(SYK):c.1057G>A (p.Ala353Thr) SNV Uncertain significance 989236 9:93637007-93637007 9:90874725-90874725

Expression for Colitis

Search GEO for disease gene expression data for Colitis.

Pathways for Colitis

Pathways related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TNF SYK NOD2 MPO IL23R IL2
2
Show member pathways
13.9 TNF SMAD4 IL23R IL2 IL1B IL17A
3
Show member pathways
13.76 TNF SMAD4 IL23R IL2 IL1B IL17A
4
Show member pathways
13.63 TNF SMAD4 IL2 IL1B IL17A IL10RB
5
Show member pathways
13.49 TNF SYK IL23R IL2 IL1B IL17A
6
Show member pathways
13.34 TNF SMAD4 IL23R IL2 IL1B IL17A
7
Show member pathways
13.29 TNF SYK NOD2 IL23R IL2 IL1B
8
Show member pathways
13.13 TNF SYK SMAD4 IL2 IL1B IL10
9
Show member pathways
13.04 TNF SYK IL1B IL10RB IL10RA CXCL8
10 12.93 SMAD4 IL23R IL2 IFNG CXCL8 CTNNB1
11
Show member pathways
12.93 TNF SYK IL2 IL1B IFNG HLA-DRB1
12
Show member pathways
12.87 TNF IL2 IL1B IL17A IL10 IFNG
13 12.84 TNF SYK IL1B IFNG HLA-DRB1
14
Show member pathways
12.72 TNF SYK IL2 IL10RB IL10RA IL10
15
Show member pathways
12.7 TNF IL2 IL1B IL17A IL10 IFNG
16 12.61 TNF SYK MPO IL2 IL1B IL17A
17
Show member pathways
12.53 IL23R IL2 IL10RB IL10RA IL10 IFNG
18 12.45 TNF SMAD4 IL2 HLA-DRB1 CHEK2
19 12.44 TNF IL1B CXCL8 ATG16L1
20
Show member pathways
12.44 TNF IL1B IL17A IFNG CXCL8
21
Show member pathways
12.44 TNF MPO IL2 IL1B IFNG
22
Show member pathways
12.43 TNF IL2 IL10RB IL10RA IL10 CXCL8
23
Show member pathways
12.36 TNF IL2 IL1B IL17A IL10 IFNG
24 12.35 TNF NOD2 IL1B CXCL8 ATG16L1
25 12.33 IL23R IL10RB IL10RA ATG16L1
26
Show member pathways
12.32 TNF SYK IL2 IL1B IL10
27 12.29 TNF IL1B IL10 CXCL8 CTNNB1
28
Show member pathways
12.28 TNF IRGM IL1B IL10RB IL10RA IL10
29 12.26 TNF SMAD4 IFNG CTNNB1
30
Show member pathways
12.25 TNF IL1B IFNG CXCL8
31
Show member pathways
12.23 TNF SMAD4 NOD2 IL23R IL2 IL1B
32 12.2 TNF IL2 IL1B IL10 CXCL8
33 12.17 TNF IL1B IFNG CTNNB1
34 12.14 TNF IL2 IL1B IFNG CXCL8
35 12.13 TNF SYK IL1B IFNG
36 12.12 TNF MPO IL2 IL10 IFNG
37
Show member pathways
12.08 IL2 IL1B IFNG HLA-DRB1
38 12.08 TNF IL23R IL1B IL17A IL10 CXCL8
39 12.06 SMAD4 IL1B IFNG CXCL8 ATG16L1
40 12.06 TNF SYK NOD2 IL1B IL10RB IL10RA
41 12.04 TNF SYK IL1B CXCL8
42 12.03 TNF IL1B IL10 IFNG CXCL8
43 12.01 TNF SMAD4 IL1B CXCL8
44
Show member pathways
11.98 SMAD4 IL23R IL17A CXCL8
45
Show member pathways
11.97 SMAD4 IL23R IL1B IL17A IFNG
46 11.97 TNF IL1B IL17A IFNG HLA-DRB1 CXCL8
47
Show member pathways
11.9 TNF MPO IL23R IL2 IL1B IL17A
48 11.88 TNF IL1B IL10 CXCL8
49
Show member pathways
11.88 TNF IL2 IFNG CXCL8
50 11.87 TNF IL2 IL1B IL10 IFNG

GO Terms for Colitis

Cellular components related to Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TNF MPO IL2 IL1B IL17A IL10

Biological processes related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.26 TNF SMAD4 NOD2 IL2 IL17A IL10
2 immune system process GO:0002376 10.2 SYK NOD2 IRGM IL23R IL2 IL17A
3 positive regulation of transcription, DNA-templated GO:0045893 10.17 TNF SMAD4 IL1B IL10 HLA-DRB1 CTNNB1
4 positive regulation of gene expression GO:0010628 10.14 TNF IL1B IFNG CXCL8 CTNNB1
5 adaptive immune response GO:0002250 10.13 SYK IL2 IL17A IFNG HLA-DRB1
6 negative regulation of cell proliferation GO:0008285 10.13 SMAD4 IL1B IL10 CXCL8 CTNNB1
7 regulation of cell proliferation GO:0042127 10.03 TNF SYK SMAD4 CTNNB1
8 inflammatory response GO:0006954 10.02 TNF IRGM IL23R IL1B IL17A IL10RB
9 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TNF NOD2 HLA-DRB1 CTNNB1
10 defense response to bacterium GO:0042742 9.99 TNF SYK NOD2 MPO IRGM IL10
11 activation of MAPK activity GO:0000187 9.97 TNF SYK NOD2 IL1B
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 TNF IL1B IL10 CTNNB1
13 defense response GO:0006952 9.96 TNF NOD2 MPO IRGM CXCL8
14 positive regulation of inflammatory response GO:0050729 9.93 TNF IL2 IL1B IFNG
15 response to lipopolysaccharide GO:0032496 9.93 NOD2 MPO IL23R IL1B IL10RA IL10
16 positive regulation of tumor necrosis factor production GO:0032760 9.92 SYK NOD2 IL17A IFNG
17 regulation of insulin secretion GO:0050796 9.91 TNF IL1B IFNG
18 cellular response to organic cyclic compound GO:0071407 9.91 TNF NOD2 IL1B
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL23R IL2 IFNG
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF NOD2 IL1B
21 positive regulation of T cell proliferation GO:0042102 9.9 IL23R IL2 IL1B
22 positive regulation of autophagy GO:0010508 9.89 IRGM IFNG ATG16L1
23 positive regulation of interferon-gamma production GO:0032729 9.89 TNF IL23R IL2 IL1B
24 positive regulation of protein complex assembly GO:0031334 9.88 TNF SYK IFNG
25 cellular response to lipopolysaccharide GO:0071222 9.88 TNF NOD2 IRGM IL1B IL10 CXCL8
26 positive regulation of epithelial to mesenchymal transition GO:0010718 9.87 SMAD4 IL1B CTNNB1
27 positive regulation of interleukin-8 production GO:0032757 9.87 TNF SYK NOD2 IL1B
28 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF IL1B IFNG
29 negative regulation of interferon-gamma production GO:0032689 9.86 NOD2 IL10 HLA-DRB1
30 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.85 TNF SMAD4 IL10
31 positive regulation of interleukin-1 beta production GO:0032731 9.85 TNF NOD2 IL17A IFNG
32 positive regulation of cytokine production GO:0001819 9.84 TNF SYK IL10 IFNG
33 regulation of synapse organization GO:0050807 9.83 TNF IL10RA IL10
34 positive regulation of phagocytosis GO:0050766 9.83 TNF NOD2 IL1B IFNG
35 negative regulation of neurogenesis GO:0050768 9.82 TNF IL1B CTNNB1
36 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.81 TNF NOD2 IL17A
37 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF IL10RB IL10RA IL10
38 positive regulation of protein phosphorylation GO:0001934 9.8 TNF IRGM IL2 IL1B IFNG HLA-DRB1
39 positive regulation of interleukin-17 production GO:0032740 9.79 NOD2 IL23R IL2
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.78 TNF IL1B IFNG
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 TNF IL1B IL10
42 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.76 SYK NOD2 IL1B
43 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.75 SYK IL23R IL1B
44 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
45 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 IL10 IFNG
46 interleukin-2-mediated signaling pathway GO:0038110 9.74 SYK IL2
47 response to molecule of bacterial origin GO:0002237 9.74 IL10 CXCL8
48 regulation of establishment of endothelial barrier GO:1903140 9.74 TNF IL1B
49 positive regulation of memory T cell differentiation GO:0043382 9.73 IL23R HLA-DRB1
50 positive regulation of osteoclast differentiation GO:0045672 9.73 TNF IL23R IL17A IFNG

Molecular functions related to Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 TNF SYK SMAD4 NOD2 MPO IRGM
2 protein kinase binding GO:0019901 9.72 SYK NOD2 IRGM CTNNB1 CHEK2
3 cytokine receptor activity GO:0004896 9.43 IL23R IL10RB IL10RA
4 cytokine activity GO:0005125 9.17 TNF IL2 IL1B IL17A IL10 IFNG
5 interleukin-10 receptor activity GO:0004920 8.96 IL10RB IL10RA

Sources for Colitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....